Yat Sun Or
2014
In 2014, Yat Sun Or earned a total compensation of $1.4M as Senior Vice President, Research & Development and Chief Scientific Officer at Enanta Pharmaceuticals, a 41% increase compared to previous year.
Compensation breakdown
| Bonus | $148,863 |
|---|---|
| Option Awards | $877,954 |
| Salary | $365,251 |
| Other | $11,369 |
| Total | $1,403,437 |
Or received $878K in option awards, accounting for 63% of the total pay in 2014.
Or also received $148.9K in bonus, $365.3K in salary and $11.4K in other compensation.
Rankings
In 2014, Yat Sun Or's compensation ranked 6,078th out of 13,032 executives tracked by ExecPay. In other words, Or earned more than 53.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,078 out of 13,032 | 53rd |
Division Manufacturing | 2,197 out of 4,967 | 56th |
Major group Chemicals And Allied Products | 732 out of 1,690 | 57th |
Industry group Drugs | 569 out of 1,369 | 58th |
Industry Pharmaceutical Preparations | 438 out of 1,042 | 58th |
Source: SEC filing on January 13, 2016.
Or's colleagues
We found two more compensation records of executives who worked with Yat Sun Or at Enanta Pharmaceuticals in 2014.
News
Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
January 20, 2023
Enanta Pharmaceuticals CEO Jay Luly's 2021 pay rises 2% to $5.3M
January 21, 2022
Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
January 21, 2021
Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
January 17, 2020
Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M
January 18, 2019